For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These groundbreaking therapies stabilize the transthyretin protein, preventing its harmful build-up and lessening